PMID- 36093924
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20221021
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 28
DP  - 2022 Sep 12
TI  - Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal 
      Glucose Levels May Also Maintain Normal Weight and Control Metabolic 
      Dysfunction-Associated Fatty Liver Disease (MAFLD).
PG  - e938365
LID - 10.12659/MSM.938365 [doi]
AB  - Worldwide, metabolic dysfunction-associated fatty liver disease (MAFLD) is the 
      most common chronic liver disease. MAFLD is associated with insulin resistance, 
      type 2 diabetes mellitus (T2DM), obesity, hypertension, and dyslipidemia. Early 
      diagnosis and management are vital to improving hepatic and cardiometabolic 
      outcomes. Dietary change, weight loss, and structured exercise are the main 
      treatment approaches for fatty liver disease. Since 2010, several investigational 
      drug treatments failed to achieve regulatory approval due to mixed and 
      unsatisfactory results. Although glucagon-like peptide 1 receptor agonists 
      (GLP1-RAs) showed initial promise as therapeutic agents, metabolic liver damage 
      can recur after monotherapy cessation. Dual incretin receptor agonists target the 
      receptors for glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide 
      (GIP). Importantly, on May 13, 2022, the US Food and Drug Administration (FDA) 
      approved tirzepatide as the first dual GLP-1 and GIP receptor agonist for the 
      treatment of T2DM. Dual incretin receptor agonists induce weight loss and enhance 
      hepatic lipid metabolism and systemic insulin sensitivity. Insulin resistance and 
      hepatic steatosis are the main contributors to the development of MAFLD. 
      Treatment with dual incretin analogs reduces hepatic steatosis, lobular 
      inflammation, liver cell damage, fibrosis, and total liver triglyceride levels. 
      The availability of dual incretin receptor agonists for patients with MAFLD may 
      result in weight control, normalizing insulin sensitivity, and reducing or even 
      reversing metabolic dysfunction and liver damage. This Editorial aims to provide 
      an update and discuss how treatment with dual incretin receptor agonists may 
      maintain normal glucose levels and weight and control MAFLD.
FAU - Ordonez-Vazquez, Ana Luisa
AU  - Ordonez-Vazquez AL
AD  - Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
FAU - Beltran-Gall, Sofia Murua
AU  - Beltran-Gall SM
AD  - Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
FAU - Pal, Shreya C
AU  - Pal SC
AD  - Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
AD  - Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 
      Mexico.
FAU - Mendez-Sanchez, Nahum
AU  - Mendez-Sanchez N
AD  - Liver Research Unit, Medical Sur Clinic Foundation, Mexico City, Mexico.
AD  - Faculty of Medicine, National Aurtonomous University of Mexico, Mexico City, 
      Mexico.
LA  - eng
PT  - Editorial
DEP - 20220912
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Incretins)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/metabolism
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Glucose/metabolism
MH  - Humans
MH  - Incretins/metabolism/therapeutic use
MH  - *Insulin Resistance
MH  - United States
MH  - Weight Loss
PMC - PMC9479660
COIS- Conflict of interest: None declared
EDAT- 2022/09/13 06:00
MHDA- 2022/09/14 06:00
PMCR- 2022/09/12
CRDT- 2022/09/12 06:13
PHST- 2022/09/12 06:13 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/09/12 00:00 [pmc-release]
AID - 938365 [pii]
AID - 10.12659/MSM.938365 [doi]
PST - epublish
SO  - Med Sci Monit. 2022 Sep 12;28:e938365. doi: 10.12659/MSM.938365.